Mild-to-moderate hypertension: The initial dose is 12.5 mg twice daily. The usual maintenance dose is 25mg twice daily which can be increased incrementally, at two to four week intervals, until a satisfactory response is achieved, to a maximum of 50 mg twice daily.
Severe hypertension: In severe hypertension the starting dose is 12.5 mg b.d. The dosage may be increased incrementally to a maximum of 50 mg t.d.s.
Heart failure: A starting dose of 6.25mg or 12.5mg may minimise a transient hypotensive effect. The usual maintenance dose is 25mg three times a day. The usual maximum dose is 150 mg daily.
Captopril must be taken 1 hour before meals to ensure maximum absorption.
Use in Child: Safety and effectiveness in pediatric patients have not been established.
Do not coadminister aliskiren with Angiten in patients with diabetes. Monitor renal function periodically.
A history of previous hypersensitivity to captopril. Captopril is contra-indicated in pregnancy and should not be used in women of child-bearing potential unless protected by effective contraception.
Neutropenia, anaemia, proteinuria, hypotension, tachycardia, rashes, usually pruritic may occur. Gastric irritation and abdominal pain may occur.
There are no available data in pregnant women to inform the drug-associated risk. Because of the potential for serious adverse reactions a decision should be made whether to discontinue nursing or to discontinue the drug.
Evaluation of the patient should include assessment of renal function before Angiten therapy and at appropriate intervals thereafter. Patients with renal impairment should not normally be treated with Angiten. Angiten should not be used in patients with aortic stenosis or outflow tract obstruction.
Correction of hypertension would be of primary concern.
Reviews
There are no reviews yet.